Myopia primary prevention
|
Myopia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myopia primary prevention On the Web |
|
American Roentgen Ray Society Images of Myopia primary prevention |
|
Risk calculators and risk factors for Myopia primary prevention |
Please help WikiDoc by more adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Saumya Easaw, M.B.B.S.[3]
Primary Prevention
There is no universally accepted method of preventing myopia. Some clinicians and researchers recommend plus power (convex) lenses in the form of single vision reading lenses or bifocals.[1] A recent Malaysian study reported in New Scientist[2] suggested that undercorrection of myopia caused more rapid progression of myopia,[3] However, the reliability of this data has been called into question.[4] Many myopia treatment studies suffer from any of a number of design drawbacks:
- Lack of adequate control group,
- Failure to mask examiners from knowledge of treatments used, etc.
Pirenzepine eyedrops had a limited effect on retarding myopic progression in a recent, placebo-control, double-blinded prospective controlled study[5].
References
- ↑ Rehm, Donald "The Myopia Myth-The Truth About Nearsightedness And How To Prevent It" Chapter 6 Published by The International Myopia Prevention Assn., 1054 Gravel Hill Road, Ligonier, PA 15658. 1981 ISBN 0-9608476-0-X
- ↑ Andy Coghlan and Michael Le Page (20 November 2002). "Eye correction is seriously short sighted". New Scientist.
- ↑ Chung K, Mohidin N, O'Leary DJ. "Undercorrection of myopia enhances rather than inhibits myopia progression." Vision Res. 2002 Oct;42(22):2555-9. PMID 12445849.
- ↑ The Wildoset Lab. "Controlling Myopia Progression - A Confusing Story". Retrieved September 1, 2006.
- ↑ Siatkowski R, Cotter S, Miller J, Scher C, Crockett R, Novack G (2004). "Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study". Arch Ophthalmol. 122 (11): 1667–74. PMID 15534128.